BioPorto A/S (CPH:BIOPOR)
1.500
+0.006 (0.40%)
Feb 21, 2025, 4:59 PM CET
BioPorto Employees
BioPorto had 29 employees as of December 31, 2023. The number of employees decreased by 3 or -9.38% compared to the previous year.
Employees
29
Change (1Y)
-3
Growth (1Y)
-9.38%
Revenue / Employee
969.61K DKK
Profits / Employee
-1.70M DKK
Market Cap
644.49M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Novo Nordisk | 77,349 |
Coloplast | 16,639 |
Genmab | 2,682 |
Demant | 22,639 |
Zealand Pharma | 253 |
H. Lundbeck | 5,707 |
Ambu A/S | 5,196 |
ALK-Abelló | 2,824 |
BioPorto News
- 24 days ago - BioPorto A/S appoints new interim Chairman of the Board - GlobeNewsWire
- 4 weeks ago - BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals - GlobeNewsWire
- 2 months ago - BioPorto commences process to appoint new Chair of the Board of Directors - GlobeNewsWire
- 3 months ago - BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 - GlobeNewsWire
- 3 months ago - BioPorto A/S to Host Third Quarter 2024 Earnings Webcast - GlobeNewsWire
- 3 months ago - BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences - GlobeNewsWire
- 4 months ago - First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital - GlobeNewsWire
- 4 months ago - BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests - GlobeNewsWire